179022-70-9Relevant academic research and scientific papers
Synthesis of imidazopyridines and purines as potent inhibitors of leukotriene A4 hydrolase
Penning, Thomas D.,Chandrakumar, Nizal S.,Desai, Bipin N.,Djuric, Stevan W.,Gasiecki, Alan F.,Malecha, James W.,Miyashiro, Julie M.,Russell, Mark A.,Askonas, Leslie J.,Gierse, James K.,Harding, Elizabeth I.,Highkin, Maureen K.,Kachur, James F.,Kim, Suzanne H.,Villani-Price, Doreen,Pyla, E. Yvonne,Ghoreishi-Haack, Nayereh S.,Smith, Walter G.
, p. 1137 - 1139 (2007/10/03)
The synthesis and biological evaluation of a series of heterocyclic analogues of the previously reported LTA4 hydrolase inhibitor 1b are described. Imidazopyridine and purine analogues are specifically highlighted with several demonstrating excellent potency in our in vitro assays, as well as good oral activity in a mouse ex vivo assay.
LTA4 Hydrolase inhibitors
-
Page 141, (2010/01/31)
The present invention provides compounds of the formula Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as proriasis, ulcerative colitis, IBD and asthma.
LTA4 HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
-
, (2008/06/13)
The present invention provides compounds of the formula Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an a
LTA4 HYDROLASE INHIBITORS
-
, (2008/06/13)
The present invention provides compounds of the formula Ar1?Q?Ar2?Y?R?Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an a
